Eosinophilic granulomatosis with polyangiitis presenting with acute polyneuropathy resembling Guillain–Barre syndrome

Mohamed Hamid, Youssef Benmoh, Cedrick Moussavou, Aziz Ahizone, Ayoub Bakal, Mohamed Ajamate, Amal Satte, Ahmed Bourazza

ABSTRACT

Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) is defined as a small- and medium-sized artery necrotizing vasculitis associated with asthma, eosinophilia, and extra neurologic granulomatosis (lung, cardiac, kidney, and skin). We report a case of EGPA with Guillain–Barre syndrome (GBS) like presentation.

Case Report: A 37-year-old man with a history of asthma was admitted for rapidly progressive symmetric flaccid areflexic tetraparesis, peripheral facial palsy, proprioceptive hypoesthesia, and thigh skin purpuric lesions. Electroneuromyography study revealed demyelinating sensory motor polyneuropathy with secondary axonal loss. Cervical MRI, cerebrospinal fluid study, and paraclinical tests were normal. Complete blood count showed hypereosinophilia and elevated erythrocyte sedimentation. Electrocardiogram and transthoracic echocardiography were normal. Spirometry revealed obstructive syndrome. Chest and paranasal sinus computed tomography (CT) demonstrated ground-glass opacities and severe pansinusitis. Skin biopsy showed necrotizing vasculitis with eosinophils and antineutrophil cytoplasmic antibody (ANCA) was negative. Clinical, laboratory, and radiologic findings met the American College of Rheumatology (ACR) EGPA criteria. The patient was treated by methylprednisolone bolus and cyclophosphamide with sensory motor recovery and no systemic relapse with 10 months follow-up.

Conclusion: Eosinophilic granulomatosis with polyangiitis may be revealed by a GBS mimicking presentation. Neurologic system can be involved in the ANCA negative EGPA. Paraclinical tests should be performed in GBS presentation to make accurate diagnosis and early treatment.

Keywords: Asthma, Eosinophilic granulomatosis with polyangiitis, Guillain–Barre syndrome, Hypereosinophilia

How to cite this article


do: 10.5348/101282Z01MH2022CR

INTRODUCTION

First described in 1951, Churg–Strauss syndrome is a systemic necrotizing vasculitis affecting small and medium vessels, associated with asthma and eosinophilia [1]. In 40%, the now named Eosinophilic granulomatosis with polyangiitis (EGPA) is associated
with antineutrophil cytoplasmic antibodies (ANCA). Eosinophilic granulomatosis with polyangiitis causes multisystemic disorders, involving lung, cardiac, skin lesions, and peripheral neuropathy [2]. We report a case of EGPA with Guillain–Barre syndrome (GBS) like presentation.

CASE REPORT

Previously treated for asthma, a 37-year-old man was admitted for rapidly progressive lower limb weakness. He had no history of diabetes, tuberculosis, smoking, or alcoholism. Three weeks before his admission, the patient was treated for tracheobronchitis. Two weeks later, he reported progressive paresthesia and numbness in both lower limbs. Three days later neurologic symptoms advanced to both upper limbs. The evolution was marked by ascending symmetric paralysis with neuropathic pain. Clinical examination found conscious patient, with supple neck. Neurological examination revealed symmetric flaccid areflexic proximodistal tetraparesis quoted to 1/5 on Medical Research Council (MRC) grading scale; proprioceptive hypoesthesia and peripheral facial palsy. Apart from thigh skin purpuric lesions, there were no other extra-neurological signs.

Guillain–Barre syndrome was suspected. Electroneuromyography demonstrated conduction block, prolonged distal motor latency with slowing motor nerve velocity and F wave absence in peroneal and tibial nerves. Sural nerve sensitive response amplitude was decreased. We conclude to demyelinating sensory motor polyneuropathy with secondary axonal loss (Table 1). Cervical MRI showed no signal abnormality and no cervical roots gadolinium enhancement. There was no albuminocytologic dissociation on cerebrospinal fluid.

### Table 1: Electroneuromyography results

Conduction block in right tibial nerve, left ulnar nerve, left median nerve with decreased motor amplitude response with slowing motor conduction velocity in right median, right ulnar, and both peroneal nerves. Absence of F wave of all nerves. Slowing sensitive conduction velocity with normal sensitive amplitude response in both sural nerves. Conclusion: demyelinating motor-sensory polyneuropathy with secondary axonal loss.

<table>
<thead>
<tr>
<th>Motor nerve conduction study</th>
<th>Stimulation–reception</th>
<th>Latency (ms)</th>
<th>Amplitude (mV)</th>
<th>Duration (ms)</th>
<th>Velocity (m/s)</th>
<th>F Wave</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median right</td>
<td>Wrist–palm</td>
<td>3.33</td>
<td>0.9</td>
<td>7.14</td>
<td>42</td>
<td>Abs</td>
</tr>
<tr>
<td></td>
<td>Above elbow–wrist</td>
<td>8.28</td>
<td>0.8</td>
<td>6.82</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median left</td>
<td>Wrist–palm</td>
<td>3.18</td>
<td>6.4</td>
<td>6.25</td>
<td>45</td>
<td>Abs</td>
</tr>
<tr>
<td></td>
<td>Above elbow–wrist</td>
<td>7.55</td>
<td>0.9</td>
<td>5.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ulnar left</td>
<td>Wrist–Adm</td>
<td>3.23</td>
<td>6.1</td>
<td>6.25</td>
<td>46</td>
<td>Abs</td>
</tr>
<tr>
<td></td>
<td>Below elbow–wrist</td>
<td>7.24</td>
<td>2.5</td>
<td>7.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ulnar right</td>
<td>Wrist–Adm</td>
<td>2.92</td>
<td>1.6</td>
<td>6.04</td>
<td>40</td>
<td>Abs</td>
</tr>
<tr>
<td></td>
<td>Below elbow–wrist</td>
<td>6.88</td>
<td>2.0</td>
<td>6.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peroneal right</td>
<td>Ankle–EDB</td>
<td>5.47</td>
<td>0.5</td>
<td>5.47</td>
<td>36</td>
<td>Abs</td>
</tr>
<tr>
<td></td>
<td>Below fib head–ankle</td>
<td>11.30</td>
<td>0.4</td>
<td>7.66</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peroneal left</td>
<td>Ankle–EDB</td>
<td>4.27</td>
<td>0.4</td>
<td>5.78</td>
<td>34</td>
<td>Abs</td>
</tr>
<tr>
<td></td>
<td>Below fib head–ankle</td>
<td>10.05</td>
<td>0.5</td>
<td>6.72</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tibial right</td>
<td>Med malleolus–Abd hallucis</td>
<td>9.31</td>
<td>2.3</td>
<td>3.96</td>
<td>39</td>
<td>Abs</td>
</tr>
<tr>
<td></td>
<td>Popliteal fosse–Med malleolus</td>
<td>14.53</td>
<td>0.6</td>
<td>3.39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tibial left</td>
<td>Med malleolus–Abd hallucis</td>
<td>10.07</td>
<td>0.8</td>
<td>4.53</td>
<td>Abs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Popliteal fosse–Med malleolus</td>
<td>17.6</td>
<td>0.3</td>
<td>3.91</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sensitive nerve conduction study</th>
<th>Stimulation–reception</th>
<th>Latency (ms)</th>
<th>Amplitude (uV)</th>
<th>Velocity (m/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sural right</td>
<td>Lat. leg malleolus</td>
<td>1.91</td>
<td>29.5</td>
<td>31</td>
</tr>
<tr>
<td>Sural left</td>
<td>Leg. lat. malleolus</td>
<td>1.82</td>
<td>26</td>
<td>30</td>
</tr>
<tr>
<td>Median left</td>
<td>III–Wrist</td>
<td>2.5</td>
<td>24.2</td>
<td>42</td>
</tr>
<tr>
<td>Median right</td>
<td>III–Wrist</td>
<td>2.34</td>
<td>26</td>
<td>44</td>
</tr>
<tr>
<td>Ulnar left</td>
<td>5th Finger–Wrist</td>
<td>1.82</td>
<td>18.6</td>
<td>46</td>
</tr>
<tr>
<td>Ulnar right</td>
<td>5th Finger–Wrist</td>
<td>1.98</td>
<td>19.2</td>
<td>47</td>
</tr>
</tbody>
</table>
study. Paraclinical tests were normal (thyroid hormone, B12, and B9 seric levels, serology for hepatitis B, C, HIV, syphilis, tuberculosis polymerase chain reaction (PCR), salivary gland biopsy, renal and hepatic tests).

Complete blood count (CBC) showed hypereosinophilia to 7200 cells/mm$^3$ with elevated erythrocyte sedimentation rate to 49 mm/h. Spirometry revealed obstructive syndrome. Electrocardiogram and transthoracic echocardiography were normal. Chest and paranasal sinus CT demonstrated ground-glass opacities (Figure 1) and severe pansinusitis (Figure 2). Skin biopsy showed necrotizing vasculitis with eosinophils (Figure 3) and ANCA were negative.

Eosinophilic granulomatosis with polyangiitis was evoked on clinical, electrophysiological, and radiological findings. Histological results confirmed the diagnosis.

The patient was treated with methylprednisolone bolus (1 g/day for three days) followed by cyclophosphamide 600 mg/m$^2$ at day 1(D1), D15, D30 then monthly. He also underwent functional rehabilitation. Evolution was favorable, with sensory and motor gradual recovery and no systemic relapse with 10 months follow-up.

**DISCUSSION**

Eosinophilic granulomatosis with polyangiitis is defined as a small- and medium-sized arteries necrotizing vasculitis associated with asthma, eosinophilia, and extra-neurologic granulomatosis. Its annual incidence is above 0.5 to 4.2 per million people, more frequent in people aged between 40- and 60-year-old with no gender predominance or ethnic predisposition [3–5].
Eosinophilic granulomatosis with polyangiitis evolves through three phases: prodromic phase marked by recurrent sinusitis, nasal polyposis, and bronchial asthma; eosinophilic phase marked by eosinophilia and organ involvement (lung, cardiac, skin, kidney) and generalized or vasculitic stage with small vessel involvement [6].

Diagnostic of EGPA is established by American College of Rheumatology (ACR) and made when four of the six criteria are met (Table 2) [1]. Case reported met the ACR criteria: acute demyelinating polyneuropathy, asthma, eosinophilia, severe pansinusitis, and necrotizing vasculitis with eosinophils on skin biopsy.

Peripheral nervous system involvement is reported in up to 76%. The typical form is multiple mononeuropathies followed by polyneuropathy (24%) and less frequently lumbar radiculopathy (3%). Central nervous system involvement is less common (seizure, confusion, and coma) but more severe regarding morbidity and mortality among patient with EGPA [7]. Ischemic optic neuropathy is the most common cranial nerve lesion reported. Facial nerve palsy as mentioned in our case is rarely reported over the literature [8]. Eosinophilic granulomatosis with polyangiitis can be differentiated in two subsets, ANCA-positive subset occurred in 38% of EGPA patients frequently presented glomerulonephritis and peripheral neuropathy, and ANCA-negative subset with lung infiltrates and endo-myocardial involvement [9]. Increased peripheral or central nervous involvement among patient with ANCA positive are frequently reported, but it doesn’t in our case. Histopathological findings of vasculitic neuropathy are marked by axonal degeneration of nerve fibers, vasculitis ischemia which induced by eosinophils derived neurotoxins. Nerve biopsy is no more mandatory criteria for EGPA diagnosis [10, 11]. In the Sable-Fourtassou et al. study [12], only 39% of the 69 EGPA patients with ANCA-negative had features of vasculitis on biopsy. Our patient had ANCA-negative with features of eosinophilia on skin biopsy. Eosinophilic granulomatosis with polyangiitis diagnosis is thought to be difficult in the prodromic phase, but should not be missed in vasculitic stage, since that early treatment improve the prognosis.

Guillain–Barre syndrome mimicking presentation is previously reported at least in nine cases. First case of EGPA mimicking GBS clinically and electrophysiologically was reported by Ng et al. [13]. Their patient had no recovery with plasmapheresis and was later confirmed to be a case of EGPA (persistent eosinophilia, eosinophilic vasculitis in sural nerve biopsy and positive ANCA). In 1998, Keven et al. [14] reported the next case presented initially with GBS-like neuropathy, later developing ANCA-positive nephritic syndrome. At least five other cases of EGPA have been mentioned, all with clinic and neurophysiologic studies suggestive of GBS [15–18]. Antineutrophil cytoplasmic antibody positivity, eosinophilia and treatment failure with intravenous immunoglobulin led to the correct diagnosis. Unlike the mentioned cases course, our case had better prognosis due to early bolus methylprednisolone and cyclophosphamide with no other organ involvement.

Eosinophilic granulomatosis with polyangiitis prognosis depends on the five-factor score (FFS) which includes age >65 years, renal dysfunction, cardiac symptoms, gastrointestinal involvement, absence of nose, ear, and throat involvement. With the presence of one factor, the five-year mortality rate is above 21%, and get to 40% with two or more factors [19]. Interestingly, the outcome is widely better with corticosteroids and immunosuppressants, with five-year survival reaching 90% [20].

CONCLUSION

We learn from this case that EGPA may be revealed by a GBS mimicking presentation. Neurologic system can be involved in the ANCA negative EGPA. Paraclinical tests should be performed in GBS presentation, leading to concise diagnosis and adequate early treatment. Unlike GBS, EGPA polyneuropathy cases improve with methylprednisolone bolus associated with immunosuppressive treatment (cyclophosphamide).

REFERENCES


**********

Author Contributions

Mohamed Hamid – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Youssef Benmoh – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Ayoub Bakal – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Aziz Ahizone – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Mohamed Ajamate – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Amal Satte – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Ahmed Bourazza – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Guarantor of Submission
The corresponding author is the guarantor of submission.

Source of Support
None.

Consent Statement
Written informed consent was obtained from the patient for publication of this article.

Conflict of Interest
Authors declare no conflict of interest.

Data Availability
All relevant data are within the paper and its Supporting Information files.

Copyright
© 2022 Mohamed Hamid et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
Submit your manuscripts at
www.edoriumjournals.com